Intrauterine insemination (IUI) is an assisted conception technique that involves the deposition of a processed semen sample in the upper uterine cavity, overcoming natural barriers to sperm ascent in the female reproductive tract. It is a cost-effective, noninvasive first-line therapy for selected patients with functionally normal tubes, and infertility due to a cervical factor, anovulation, moderate male factor, unexplained factors, immunological factor, and ejaculatory disorders with clinical pregnancy rates per cycle ranging from 10 to 20%. It, however, has limited use in patients with endometriosis, severe male factor infertility, tubal factor infertility, and advanced maternal age ≥ 35 years. IUI may be performed with or without ovarian stimulation. Controlled ovarian stimulation, particularly with low-dose gonadotropins, with IUI offers significant benefit in terms of pregnancy outcomes compared with natural cycle or timed intercourse, while reducing associated COH complications such as multiple pregnancies and ovarian hyperstimulation syndrome. Important prognostic indicators of success with IUI include age of patient, duration of infertility, stimulation protocol, infertility etiology, number of cycles, timing of insemination, number of preovulatory follicles on the day of hCG, processed total motile sperm > 10 million, and insemination count > 1 × 106 with > 4% normal spermatozoa. Alternative insemination techniques, such as Fallopian tube sperm perfusion, intracervical insemination, and intratubal insemination, provide no additional benefit compared to IUI. A complete couple workup that includes patient history, physical examination, and clinical and laboratory investigations is mandatory to justify the choice in favor of IUI and guide alternative patient management, while individualizing the treatment protocol according to the patient characteristics with a strict cancelation policy to limit multi-follicular development may help optimize IUI pregnancy outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676579 | PMC |
http://dx.doi.org/10.1007/s13224-017-1060-x | DOI Listing |
Case Rep Womens Health
March 2025
Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, Osaka 593-8304, Japan.
Intramural pregnancy (IMP) is an extremely rare form of ectopic pregnancy (EP), typically associated with previous uterine trauma, adenomyosis, or assisted reproductive technology (ART), such as embryo transfer (ET). Despite its potentially life-threatening nature, the absence of definitive preoperative diagnostic criteria for IMP complicates its early detection and management, especially in patients without known risk factors. Additionally, management becomes more challenging when there is an elevated risk of hemorrhage.
View Article and Find Full Text PDFJ Perinat Med
January 2025
1st Department of Obstetrics and Gynecology, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
The prevalence of artificial reproductive technologies (ART), such as intra-uterine insemination (IUI), fertilization (IVF), and intracytoplasmic sperm injection (ICSI), has surged in response to the global increase in infertility rates, now impacting 17.5 % of couples. With over nine million babies born through ART, the safety and efficacy of these methods are largely recognized; however, emerging concerns regarding their association with prenatal and long-term health risks, especially cardiovascular disease (CVD), necessitate a thorough examination.
View Article and Find Full Text PDFJ Hum Reprod Sci
December 2024
Department of Biostatistics, JIPMER, Puducherry, India.
Background: Intrauterine insemination (IUI) is an effective and inexpensive method of managing patients with unexplained and male factor infertility. It is attempted before proceeding to more invasive assisted reproductive techniques such as fertilisation and intracytoplasmic sperm injection. Numerous semen parameters have been assessed to indicate successful outcomes with IUI.
View Article and Find Full Text PDFF S Rep
December 2024
Ferring Pharmaceuticals Inc., Parsippany, New Jersey.
Objective: To evaluate the current utilization of advanced practice providers (APPs) within the field of reproductive endocrinology and infertility.
Design: Cross-sectional.
Setting: Web-based.
Obstet Gynecol Sci
January 2025
Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong.
This systematic review and meta-analysis aimed to summarize the pregnancy outcomes of women di-agnosed with genital tuberculosis (GTB) who spontaneously conceived or underwent intrauterine in-semination (IUI) or in vitro fertilization (IVF) after being treated with antitubercular therapy (ATT). Pub-lications from the PubMed, Medline, Embase, Ovid, Scopus, Web of Science, and Google Scholar data-bases were searched from December 20, 2021, to March 5, 2022. The outcomes are presented as pooled averages with 95% confidence intervals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!